Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miles Congreve

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Drug Discovery Today|October 14, 2003
A 'rule of three' for fragment-based lead discovery?Miles Congreve, Robin Carr, Chris Murray, et al.
Future Medicinal Chemistry|May 9, 2013
Ask the experts: past, present and future of the rule of fiveJonathan Baell, Miles Congreve, Paul Leeson, et al.
Journal of Medicinal Chemistry|May 7, 2008
Recent developments in fragment-based drug discoveryMiles Congreve, Gianni Chessari, Dominic Tisi, et al.
Trends in Pharmacological Sciences|April 3, 2012
New insights from structural biology into the druggability of G protein-coupled receptorsJonathan S Mason, Andrea Bortolato, Miles Congreve, et al.
Expert Opinion on Drug Discovery|October 20, 2018
Targeting adenosine A<sub>2A</sub> receptor antagonism for treatment of cancerMiles Congreve, Giles A Brown, Alexandra Borodovsky, et al.
Nature Reviews. Drug Discovery|August 3, 2004
Fragment-based lead discoveryDavid C Rees, Miles Congreve, Christopher W Murray, et al.
Cell|April 4, 2020
Impact of GPCR Structures on Drug DiscoveryMiles Congreve, Chris de Graaf, Nigel A Swain, et al.
Journal of Medicinal Chemistry|May 28, 2011
Progress in structure based drug design for G protein-coupled receptorsMiles Congreve, Christopher J Langmead, Jonathan S Mason, et al.
Drug Discovery Today|July 19, 2005
Fragment-based lead discovery: leads by designRobin A E Carr, Miles Congreve, Christopher W Murray, et al.
Nature|June 13, 2003
Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1BRob L M van Montfort, Miles Congreve, Dominic Tisi, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Drug Discovery Today|October 14, 2003
A 'rule of three' for fragment-based lead discovery?Miles Congreve, Robin Carr, Chris Murray, et al.
Future Medicinal Chemistry|May 9, 2013
Ask the experts: past, present and future of the rule of fiveJonathan Baell, Miles Congreve, Paul Leeson, et al.
Journal of Medicinal Chemistry|May 7, 2008
Recent developments in fragment-based drug discoveryMiles Congreve, Gianni Chessari, Dominic Tisi, et al.
Trends in Pharmacological Sciences|April 3, 2012
New insights from structural biology into the druggability of G protein-coupled receptorsJonathan S Mason, Andrea Bortolato, Miles Congreve, et al.
Expert Opinion on Drug Discovery|October 20, 2018
Targeting adenosine A<sub>2A</sub> receptor antagonism for treatment of cancerMiles Congreve, Giles A Brown, Alexandra Borodovsky, et al.
Nature Reviews. Drug Discovery|August 3, 2004
Fragment-based lead discoveryDavid C Rees, Miles Congreve, Christopher W Murray, et al.
Cell|April 4, 2020
Impact of GPCR Structures on Drug DiscoveryMiles Congreve, Chris de Graaf, Nigel A Swain, et al.
Journal of Medicinal Chemistry|May 28, 2011
Progress in structure based drug design for G protein-coupled receptorsMiles Congreve, Christopher J Langmead, Jonathan S Mason, et al.
Drug Discovery Today|July 19, 2005
Fragment-based lead discovery: leads by designRobin A E Carr, Miles Congreve, Christopher W Murray, et al.
Nature|June 13, 2003
Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1BRob L M van Montfort, Miles Congreve, Dominic Tisi, et al.
Pageof 6